Long Term Investment, Biotech & High Yield Dividend Stocks

[califax]

Biotech Calendar: Key Dates for June

By Adam Feuerstein 06/01/10 - 06:00 AM EDT
http://www.thestreet.com/story/10769834/1/biotech-calendar-key-dates-for-june.html

May 29-June 3
The American Urological Association annual meeting.
June 2
FDA advisory panel meets to review AstraZeneca's(AZN) Numax for respiratory syncytial virus.
June 3
BioDelivery Sciences(BDSI) analyst/investor meeting.
Johnson & Johnson(JNJ) analyst/investors meeting.
June 4-8
The American Society of Clinical Oncology (ASCO) annual meeting. Data presentation expected from Celldex Therapeutics(CLDX), Ziopharm(ZIOP), Delcath Systems(DCTH), Pfizer(PFE), Celgene(CELG) -- and too many other companies to mention here.
June 4
Cell Therapeutics(CTIC) annual shareholder meeting.
June 10
FDA advisory panel meets to review Novartis'(NVS) oral multiple sclerosis drug Gilenia. FDA's briefing materials should be posted to the agency's web site on June 8. The Gilenia panel is also important for Biogen Idec(BIIB), Teva(TEVA) and Merck-Serono, which market current injectable MS drugs.
June 10-13
European Hematological Association meeting.
June 11
FDA approval decision date for Questcor Pharmaceuticals'(QCOR) Acthar Gel for infantile spasms.
June 16
Genzyme(GENZ) annual shareholder meeting.
June 16-19
European League Against Rheumatism meeting. Lupus data presentations from Human Genome Sciences(HGSI) and UCB/Immunomedics(IMMU).
International Society for Stem Cell Research meeting.
June 18
FDA advisory panel meets to review Boehringer Ingelheim's filbanserin for the treatment of female sexual dysfunction. The filbanserin panel could also impact Biosante Pharmaceuticals(BPAX) and its competing female libido drug LibiGel, currently in phase III studies.
June 24
FDA approval decision date for AstraZeneca's Numax for respiratory syncytial virus.
Ligand Pharmaceuticals(LGND) analyst/investor day.
June 25-29
American Diabetes Association annual meeting.
Sometime in June
Phase III study results from Affymax's(AFFY) anemia drug Hematide.